Older Adults Likely to Be Excluded From COVID-19 Trials
Fifty percent of phase 3 clinical trials and 100 percent of vaccine trials at risk for excluding older adults
Mortality Below 40 Percent for COVID-19 Patients Put on ECMO
Cumulative incidence of in-hospital mortality estimated to be 37.4 percent at 90 days
Antibodies Decrease With Time After COVID-19 Symptom Onset
For all donors of convalescent plasma, drop seen in anti-RBD antibody levels from first to last donation
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of...
September 2020 Briefing – Pulmonology
Here are what the editors at HealthDay consider to be the most important developments in Pulmonology for September 2020. This roundup includes the latest...
Bronchitis in Early Childhood Linked to Later Lung Disease
Lung diseases occurring later in life more likely to be asthma, pneumonia rather than chronic bronchitis
No Moderna COVID-19 Vaccine Expected Until Next Spring
Company will not be ready to seek U.S. approval for the vaccine until at least late January
Review: Children, Teens Have Lower Susceptibility to SARS-CoV-2
Most studies consistent with lower seroprevalence for children versus adults; similar for teens, adults
GI Complications More Common in Critically Ill With COVID-19
More transaminitis, severe ileus, bowel ischemia observed versus patients with non-COVID-19 acute respiratory distress
Atezolizumab Prolongs Survival in NSCLC With PD-L1 Expression
Overall survival longer than for chemotherapy in metastatic NSCLC with high PD-L1 expression
